![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
623kB |
Preview |
PDF (Supplementary Materials)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
| Item Type: | Article |
|---|---|
| Title: | Functional classification of TP53 mutations in acute myeloid leukemia |
| Creators Name: | Dutta, S., Pregartner, G., Rücker, F.G., Heitzer, E., Zebisch, A., Bullinger, L., Berghold, A., Döhner, K. and Sill, H. |
| Abstract: | Mutations of the gene occur in a subset of patients with acute myeloid leukemia (AML) and confer an exceedingly adverse prognosis. However, whether different types of mutations exert a uniformly poor outcome has not been investigated yet. Here, we addressed this issue by analyzing data of 1537 patients intensively treated within protocols of the German-Austrian AML study group. We classified mutations depending on their impact on protein structure and according to the evolutionary action (EAp53) score and the relative fitness score (RFS). In 98/1537 (6.4%) patients, 108 mutations were detected. While the discrimination depending on the protein structure and the EAp53 score did not show a survival difference, patients with low-risk and high-risk AML-specific RFS showed a different overall survival (OS; median, 12.9 versus 5.5 months, = 0.017) and event-free survival (EFS; median, 7.3 versus 5.2 months, = 0.054). In multivariable analyses adjusting for age, gender, white blood cell count, cytogenetic risk, type of AML, and TP53 variant allele frequency, these differences were statistically significant for both OS (HR, 2.14; 95% CI, 1.15-4.0; = 0.017) and EFS (HR, 1.97; 95% CI, 1.06-3.69; = 0.033). We conclude that the AML-specific RFS is of prognostic value in patients with TP53-mutated AML and a useful tool for therapeutic decision-making. |
| Keywords: | Acute Myeloid Leukemia, TP53 Mutations, Functional Classification, Relative Fitness Core, Prognosis |
| Source: | Cancers |
| ISSN: | 2072-6694 |
| Publisher: | MDPI |
| Volume: | 12 |
| Number: | 3 |
| Page Range: | 637 |
| Date: | 10 March 2020 |
| Official Publication: | https://doi.org/10.3390/cancers12030637 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
